Autolus Therapeutics (AUTL) announces that the first patient has been dosed in its Phase 1 BOBCAT trial of obecabtagene autoleucel in patients with progressive multiple sclerosis, PMS. The patient was treated at University College London Hospitals NHS Foundation Trust, UCLH, a leading CAR T and neurological disorders treatment center in the United Kingdom and, with UCL, development partner of Autolus for obe-cel.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics: Promising Developments and Strategic Initiatives Drive Buy Rating
- Autolus Therapeutics management to meet virtually with Needham
- ArriVent Biopharma appoints Brent Rice as chief commercial officer
- Autolus Therapeutics announces abstract submitted to ACR Convergence 2025
- Autolus Therapeutics’ Earnings Call Highlights Growth and Challenges